CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,893 enrolled
Drug / intervention
Influenza virus vaccine +1 morebiological
Likely dose
Influenza virus vaccine administered as two intramuscular injections 4 weeks apart (ages 3-8 years) or one injection (ages 9-64 years)AI-extracted
Key inclusion· 1
  • Healthy subjects aged 3 to 64 years
Key exclusion· 5
  • Receipt of other investigational products within 3 months
  • Receipt of other vaccine within 1 month
  • Allergy to eggs, egg products, or any other vaccine component
  • Laboratory confirmed influenza disease within 6 months

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00464672
NCT00464672Phase 3Completed

A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years

Novartis·interventional·Posted Apr 24, 2007·Updated Oct 1, 2015

In Brief

A Phase 3 clinical trial evaluating Influenza virus vaccine and Comparator influenza vaccine for Influenza. Completed, enrolled 1,893 participants across 2 sites.

Detailed Summary

This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide countries, according to the US FDA Draft Guidance for Industry "Clinical data needed to support the licensure of trivalent inactivated influenza vaccine", issued in March 2006, and to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine already licensed in US. The purpose of the control arm is primarily to provide a comparative assessment for safety, not immunogenicity or effectiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesArgentina
CollaboratorsNovartis Vaccines

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 24, 2007
Enrollment StartApr 1, 2007
Primary CompletionJul 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 19.2 years ago

Interventions

Influenza virus vaccinebiological

Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.

Comparator influenza vaccinebiological

Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.